Single shot Covid-19 vaccine approved in US

United States regulators have officially approved the single-shot Johnson & Johnson coronavirus vaccine, the third jab to be authorised in the country.

The vaccine is set to be a cost-effective alternative to the Pfizer and Moderna vaccines, and can be stored in a refrigerator instead of a freezer.

Trials found it prevented serious illness but was 66% effective overall when moderate cases were included.

The vaccine is made by the Belgian firm Janssen.

The company has agreed to provide the US with 100 million doses by the end of June. The first doses could be available to the US public as early as next week.

The UK, EU and Canada have also ordered doses, and 500 million doses have also been ordered through the Covax scheme to supply poorer nations.

President Joe Biden hailed it as “exciting news for all Americans, and an encouraging development”, but warned that the “fight is far from over”.

“Though we celebrate today’s news, I urge all Americans – keep washing your hands, stay socially distanced, and keep wearing masks,” he said in a statement.

“As I have said many times, things are still likely to get worse again as new variants spread, and the current improvement could reverse.”

The authorisation by the US Food and Drug Administration (FDA) came after an external committee of experts unanimously backed the vaccine.

Results from trials conducted in the US, South Africa and Brazil showed it was more than 85% effective at preventing serious illness, and 66% effective overall when moderate cases were included.

Notably, there were no deaths among participants who had received the vaccine and no hospital admissions after 28 days post-vaccine.

Overall protection was lower in South Africa and Brazil, where virus variants have become dominant, but defence against severe or critical illness was “similarly high”.

South Africa began administering the unapproved Johnson & Johnson jab to healthcare workers as part of a study earlier this month. It came after after initial trials suggested the Oxford-AstraZeneca vaccine offered “minimal protection”against mild disease from the variant dominant in large parts of the country.

So far the only other country to approve the vaccine for emergency use is Bahrain, which gave it the green light on February 25.

Because the vaccine will require fewer doses than its two-shot Pfizer and Moderna counterparts, it will also require fewer vaccine appointments and medical staff.